Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
TauTona Group is a vertically-integrated operational fund founded in 2010 by Geoffrey C. Gurtner, MD, and Michael Longaker, MD, both professors from the Stanford School of Medicine. The firm is headquartered in Redwood City, California, and has established itself as a key player in the healthcare investment space. TauTona Group focuses on creating, investing in, and developing solutions in medtech, biotech, and regenerative medicine, specifically targeting unmet clinical needs in healthcare.
Since its inception, TauTona Group has operated under a sustainable investment model that supports the evaluation, design, testing, and development of disruptive ideas. The firm has developed a differentiated development process that aims to de-risk projects from ideation to commercialization. This approach has allowed them to build a portfolio of notable medical technologies that contribute to improving healthcare outcomes and reducing costs.
TauTona Group invests in innovative medical technologies that aim to enhance healthcare outcomes while simultaneously reducing costs. The firm targets early-stage investments, specifically in the pre-seed, seed, and Series A stages. Their investment strategy encompasses sectors such as healthcare, biotech, and medtech, with a particular emphasis on regenerative medicine.
The organization’s sustainable investment model is designed to support the entire lifecycle of product development, from evaluation and design to testing and commercialization. TauTona Group seeks to partner with founders who are committed to addressing significant clinical needs and who possess a strong vision for their innovations. Their differentiated development process is a key aspect of their strategy, as it helps to mitigate risks associated with bringing new medical technologies to market.
TauTona Group has developed several notable products that exemplify their focus on innovative medical technologies:
These products reflect TauTona Group's commitment to addressing unmet clinical needs and improving healthcare outcomes through innovative solutions.
Geoffrey C. Gurtner, MD - Co-Founder & Managing Partner. Geoffrey has a background in medicine and entrepreneurship, with a focus on developing innovative medical technologies.
Michael Longaker, MD - Co-Founder and General Partner. Michael is an expert in regenerative medicine and has led numerous initiatives in healthcare innovation.
Mike Blanchette - Chief Operating Officer. Mike oversees the operational aspects of the firm, ensuring efficient management of resources and projects.
Kellen Chen - Head of Research. Kellen leads research initiatives, focusing on the evaluation and development of new medical technologies.
Susan Hale - Head of Quality and Regulatory. Susan ensures that all products meet regulatory standards and quality benchmarks.
Marta Bulaich - Marketing Development. Marta is responsible for marketing strategies and outreach efforts to promote the firm's portfolio companies.
Submit your pitch through their website contact form for consideration.
What are TauTona Group's investment criteria?
TauTona Group focuses on early-stage investments in healthcare, specifically in the pre-seed, seed, and Series A stages. They seek innovative medical technologies that address unmet clinical needs and have the potential to improve healthcare outcomes while reducing costs.
How can founders apply or pitch to TauTona Group?
Founders interested in pitching to TauTona Group should prepare a detailed presentation that outlines their technology, market potential, and the clinical need it addresses. A warm introduction is preferred, but cold outreach is also accepted.
What makes TauTona Group different from other investors?
TauTona Group's vertically-integrated operational model sets it apart from traditional venture capital firms. They not only invest in startups but also actively participate in the development process, providing resources and expertise to help de-risk projects from ideation to commercialization.
What is the geographic scope of TauTona Group's investments?
The firm primarily invests in North America, focusing on startups that are developing innovative solutions in healthcare and biotech.
What is TauTona Group's approach to post-investment involvement?
TauTona Group takes an active role in supporting their portfolio companies, offering operational support, mentorship, and access to their network of industry experts. They aim to help startups navigate the challenges of bringing new medical technologies to market.
What is the typical check size for investments made by TauTona Group?
While specific check sizes are not disclosed, TauTona Group focuses on early-stage investments, which typically range from pre-seed to Series A funding rounds.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.